Practical Considerations for Venetoclax Plus HMA for Chemotherapy-Ineligible AML

At a median follow-up of 61.2 months, zanabrutinib demonstrated superior PFS vs bendamustine and rituximab in patients with CLL and SLL.

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Researchers at Stanford University have conducted a phase 1 clinical trial evaluating the combination of a bispecific CAR T-cell therapy targeting CD19 and CD22 with NKTR-255.

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Median duration on bezuclastinib was 56 weeks vs 40 weeks for placebo in non-advanced systemic mastocytosis, the phase 2 Summit trial reported.

From 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.